A case of acute liver failure due to carfilzomib in multiple myeloma.

Tytuł:: A case of acute liver failure due to carfilzomib in multiple myeloma.
Autorzy:: Kathi PR; Wayne State University School of Medicine, Detroit, Michigan.
Tama M; Wayne State University School of Medicine, Detroit, Michigan.
Kundumadam S; Wayne State University School of Medicine, Detroit, Michigan.
Naylor P; Wayne State University School of Medicine, Detroit, Michigan.
Mutchnick M; Wayne State University School of Medicine, Detroit, Michigan.
Źródło:: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2018 Dec; Vol. 43 (6), pp. 918-920. Date of Electronic Publication: 2018 Jul 03.
Typ publikacji:: Case Reports
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell Pub.
Original Publication: Oxford : Blackwell Scientific Publications, c1987-
MeSH Terms:: Antineoplastic Agents/*adverse effects
Liver Failure, Acute/*chemically induced
Multiple Myeloma/*drug therapy
Oligopeptides/*adverse effects
Antineoplastic Agents/administration & dosage ; Chemical and Drug Induced Liver Injury/etiology ; Chemical and Drug Induced Liver Injury/pathology ; Humans ; Liver Failure, Acute/pathology ; Liver Function Tests ; Male ; Middle Aged ; Oligopeptides/administration & dosage
Contributed Indexing:: Keywords: Carfilzomib; acute liver failure; drug induced liver injury; multiple myeloma
Substance Nomenclature:: 0 (Antineoplastic Agents)
0 (Oligopeptides)
72X6E3J5AR (carfilzomib)
Entry Date(s):: Date Created: 20180704 Date Completed: 20190118 Latest Revision: 20190118
Update Code:: 20240105
DOI:: 10.1111/jcpt.12741
PMID:: 29969517
: Raport

Pełny tekst

What Is Known and Study Objective: Carfilzomib is a newer drug approved for the treatment of relapsing and refractory multiple myeloma. It has been rarely associated with acute liver failure (ALF).
Case Summary: We present a case of 58-year-old man presenting with abnormal liver function tests and subsequently diagnosed with ALF due to carfilzomib. Liver enzymes improved significantly after discontinuation of the drug.
What Is New and Conclusion: Even though ALF due to carfilzomib has been documented rarely in clinical studies, no detailed case report has been published so far. Patients on carfilzomib should be monitored for ALF, and prompt discontinuation of drug is necessary in such cases.
(© 2018 John Wiley & Sons Ltd.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja